NCT01121939: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers |
|
|
| Completed | 2 | 43 | US | Bevacizumab, Avastin, Pertuzumab, Omnitarg, 2C4, Sandostatin LARĀ® Depot, Octreotide | SCRI Development Innovations, LLC, Genentech, Inc. | Neuroendocrine Carcinoma | 02/15 | 08/15 | | |